MAOA gene polymorphisms and response to mirtazapine in major depression

Tzeng, Dong‐Sheng; Chien, Chia-Chang; Lung, For‐Wey; Yang, Chun Yuh

doi:10.1002/hup.1024

Cited by 36 publications

(27 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Long MAO-A alleles (3a, 4, 5) were associated with slower and less efficient overall response of antidepressant treatment in MDD females [83]. MDD patients with short-form VNTR had greater response to mirtazapine [84]. Other studies, however, found no association between MAO-A and antidepressant treatment response [76,85].…”

Section: Monoamine Oxidase Amentioning

confidence: 95%

Advances in Biomarkers of Major Depressive Disorder

Huang

Lin

2015

Advances in Clinical Chemistry

View full text Add to dashboard Cite

Section: Monoamine Oxidase Amentioning

confidence: 95%

Advances in Biomarkers of Major Depressive Disorder

Huang

Lin

2015

Advances in Clinical Chemistry

View full text Add to dashboard Cite

“…133,[143][144][145][146][147][148][149][150][151] No association findings with antidepressant response can also be found in the literature. 81,152,153 Moreover, it has been reported that the 941T>G polymorphism (rs6323) in the MAOA gene is associated with mirtazapine response in girls and women.…”

Section: Monoamine Oxidase Amentioning

confidence: 98%

Pharmacogenetics of antidepressant response

Porcelli

Drago

Fabbri

et al. 2011

J Psychiatry Neurosci

161

103

View full text Add to dashboard Cite

87Personalized medicine -the adaptation of therapies based on an individual's genetic and molecular profile -is one of the most promising aspects of modern medicine. The identification of the relation between genotype and drug response, including both the therapeutic effect and side effect profile, is expected to deeply affect medical practice. In this paper, we review the current knowledge about the genes related to antidepressant treatment response and provide methodologic proposals for future studies. We have mainly focused on genes associated with pharmacodynamics, for which a list of promising genes has been identified despite some inconsistency across studies. We have also synthesized the main results for pharmacokinetic genes, although so far they seem less relevant than those for pharmaco dynamic genes. We discuss possible reasons for these inconsistent findings and propose new study designs.

show abstract

“…With regard to MAOA µVNTR, some studies found that the short form was associated with greater mirtazapine [31] and fluoxetine response [28], while others provided negative findings [6,32]. …”

Section: Discussionmentioning

confidence: 99%

TPH1, MAOA, Serotonin Receptor 2A and 2C Genes in Citalopram Response: Possible Effect in Melancholic and Psychotic Depression

Arias

Fabbri²,

Gressier³

et al. 2012

Neuropsychobiology

View full text Add to dashboard Cite

Background: Serotonergic genes have been widely investigated regarding antidepressant response in major depressive disorder (MDD) but results are still not univocal. Methods: 159 MDD patients treated with citalopram were genotyped and evaluated by the 21-item Hamilton Depression Rating Scale at the beginning and every 4 weeks during the 12-week follow-up. Four serotonin-related genetic variants were tested for association with treatment outcome: tryptophane hydroxylase 1 (TPH1) rs1800532, monoamine oxidase A µVNTR, serotonin 2A receptor rs6311 and serotonin 2C receptor rs6318. The effect of these polymorphisms was tested both in the whole sample and in depressive subtypes with usually higher clinical severity: psychotic and melancholic MDD. Results: No effect on response, remission and symptom improvement was found for the four polymorphisms. However, rs1800532 was found to affect the outcome depending on the MDD subtype: the A allele predicted worse response both in MDD with psychotic (F_{(6, 378)} = 2.90; p = 0.009) and melancholic (F_{(6, 381)} = 2.86; p = 0.0097) features. Conclusions: The A allele at TPH1 rs1800532 may be associated with citalopram efficacy only in melancholic and psychotic MDD. These results suggest the usefulness of investigating the effect of genetic variants in conjunction with specific clinical features.

show abstract

MAOA gene polymorphisms and response to mirtazapine in major depression

Abstract: The genetic polymorphisms in the MAOA promoter region may be associated with treatment response to mirtazapine.

Cited by 36 publications

References 38 publications

Advances in Biomarkers of Major Depressive Disorder

Advances in Biomarkers of Major Depressive Disorder

Pharmacogenetics of antidepressant response

TPH1, MAOA, Serotonin Receptor 2A and 2C Genes in Citalopram Response: Possible Effect in Melancholic and Psychotic Depression

Contact Info

Product

Resources

About